Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Effect Of CP-778,875 On HDL-Cholesterol In Adult Subjects With Dyslipidemia And Type 2 Diabetes Mellitus
1 other identifier
interventional
84
1 country
31
Brief Summary
To assess the effect of CP-778,875 on HDL-C cholesterol in adult subjects with dyslipidemia and type 2 diabetes
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_2
Started Jul 2006
Shorter than P25 for phase_2
31 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 12, 2006
CompletedFirst Posted
Study publicly available on registry
May 16, 2006
CompletedStudy Start
First participant enrolled
July 1, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2007
CompletedMay 7, 2009
May 1, 2009
May 12, 2006
May 6, 2009
Conditions
Outcome Measures
Primary Outcomes (1)
HDL-C Safety and Efficacy
Interventions
Eligibility Criteria
You may qualify if:
- HDL-C \< or = 45 mg/dL for men and \< or = 55 mg/dL for women
- Triglycerides between 150-500 mg/dL
- Fasting Plasma Glucose 140-240 mg/dL
You may not qualify if:
- Known cardiovascular, carotid, or peripheral vascular disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pfizerlead
Study Sites (31)
Pfizer Investigational Site
Anniston, Alabama, 36207, United States
Pfizer Investigational Site
Huntsville, Alabama, 35801, United States
Pfizer Investigational Site
Greenbrae, California, 94904, United States
Pfizer Investigational Site
Los Angeles, California, 90057, United States
Pfizer Investigational Site
Walnut Creek, California, 94598, United States
Pfizer Investigational Site
DeFuniak Springs, Florida, 32435, United States
Pfizer Investigational Site
Destin, Florida, 32541, United States
Pfizer Investigational Site
Jupiter, Florida, 33458, United States
Pfizer Investigational Site
Melbourne, Florida, 32901, United States
Pfizer Investigational Site
Atlanta, Georgia, 30342, United States
Pfizer Investigational Site
Conyers, Georgia, 30094, United States
Pfizer Investigational Site
Chicago, Illinois, 60612, United States
Pfizer Investigational Site
Iowa City, Iowa, 52242, United States
Pfizer Investigational Site
Lexington, Kentucky, 40504, United States
Pfizer Investigational Site
Baltimore, Maryland, 21201, United States
Pfizer Investigational Site
Springfield, Missouri, 65807, United States
Pfizer Investigational Site
Omaha, Nebraska, 68131, United States
Pfizer Investigational Site
Las Vegas, Nevada, 89106, United States
Pfizer Investigational Site
Mount Vernon, New York, 10550, United States
Pfizer Investigational Site
Oklahoma City, Oklahoma, 73103, United States
Pfizer Investigational Site
Tulsa, Oklahoma, 74136, United States
Pfizer Investigational Site
Kingsport, Tennessee, 37660, United States
Pfizer Investigational Site
Bryan, Texas, 77802, United States
Pfizer Investigational Site
Houston, Texas, 77030, United States
Pfizer Investigational Site
San Antonio, Texas, 78229, United States
Pfizer Investigational Site
Newport News, Virginia, 23606, United States
Pfizer Investigational Site
Richmond, Virginia, 23225, United States
Pfizer Investigational Site
Richmond, Virginia, 23249, United States
Pfizer Investigational Site
Richmond, Virginia, 23294, United States
Pfizer Investigational Site
Yakima, Washington, 98902, United States
Pfizer Investigational Site
Milwaukee, Wisconsin, 53209, United States
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
May 12, 2006
First Posted
May 16, 2006
Study Start
July 1, 2006
Study Completion
June 1, 2007
Last Updated
May 7, 2009
Record last verified: 2009-05